BLLN — BillionToOne, Inc.

Summary of BillionToOne Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $83.5 million, up 117% year-over-year (YoY) from $38 million in Q3 2024.
• Annualized Revenue Run Rate (ARR): $334 million, a sequential increase of approximately $69 million from Q2 2025.
• Gross Margin: 70%, a 17 percentage point increase from 53% in Q3 2024.
• Operating Income: $9.6 million with an operating margin of 11.5%, marking the first quarter of positive GAAP operating income.
• Net Income: $1.5 million or $0.10 per diluted share, compared to a net loss of $14.9 million in Q3 2024.
• Cash Position: Approximately $195 million in cash and equivalents at the end of Q3, bolstered by a successful IPO raising $314 million in gross proceeds.

2. Strategic Updates and Business Highlights

• IPO Milestone: Completed a successful IPO on NASDAQ, raising significant capital to support growth.
• Product Differentiation: Focus on unique technology (smNGS and QCT) driving high sensitivity and precision in molecular diagnostics, particularly in prenatal and oncology markets.
• Test Volume Growth: 51% YoY increase in test volume, totaling 163,000 tests in Q3.
• Oncology Growth: Oncology revenue surged 664% YoY to $8.7 million, reflecting strong demand for Northstar Select and Response tests.
• Partnerships and Publications: Secured an exclusive agreement with Johnson & Johnson for companion diagnostics and published significant clinical studies validating product efficacy.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Expected total revenue between $293 million and $299 million, indicating 92% to 96% growth compared to 2024.
• Q4 2025 Revenue Expectations: Projected between $84 million and $90 million, representing growth of over 86% to 100% YoY.
• Profitability: Anticipate continued positive GAAP operating income for both Q4 and the full year of 2025.

4. Bad News, Challenges, or Points of Concern

• Market Competition: Despite current growth, the introduction of competitive products (e.g., Fetal Focus assay) may pose future challenges, although management reported no immediate impact on business.
• Investment in EMR: Increased investment in electronic medical records (EMR) systems is necessary to facilitate broader adoption, which may require significant resources and time.
• Negative Mix Shift: The growing oncology segment, while rapidly expanding, has lower gross margins compared to prenatal products, potentially impacting overall gross margin stability.

5. Notable Q&A Insights

• 2026 Profitability: Management indicated a commitment to maintaining profitability in 2026, though specific guidance will be provided at a later date.
• Oncology Coverage: Anticipated Medicare coverage for Northstar Response by the end of 2026, with ongoing investments in clinical studies to support this goal.
• Sales Force Expansion: Plans to add 8-10 representatives for prenatal and 4-6 for oncology per quarter, maintaining a disciplined growth strategy.
• ASP Growth Drivers: Significant contributions to average selling price (ASP) growth from expanded payer coverage and Medicaid adoption of the UNITY Carrier panel.

Overall, BillionToOne demonstrated robust growth in Q3 2025, achieving significant financial milestones while positioning itself for future expansion and profitability despite competitive pressures and the need for strategic investments.